Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.

ABSTRACT: Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of MM cells to bortezomib remains a clinical concern. This study aimed to highlight the role of p53-induced RING-H2 (Pirh2) in the acquisition of bortezomib resistance in MM and to clarify the function and mechanism of action of Pirh2 in MM cell growth and resistance, thereby providing the basis for new therapeutic targets for MM. The proteasome inhibitor bortezomib has been established as one of the most effective drugs for treating MM. We demonstrated that bortezomib resistance in MM cells resulted from a reduction in Pirh2 protein levels.

SUBMITTER: Yang L 

PROVIDER: S-EPMC6107487 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature